Scot H Simpson i wsp. Mortality risk among sulfonylureas: a systematic review and network meta-analysis , LINK: The Lancet Diabetes & Endocrinology online
Inconsistency was low for the network meta-analysis of all-cause mortality, and the relative risk of death compared with glibenclamide was 0·65 (95% credible interval 0·53—0·79) for gliclazide, 0·83 (0·68—1·00) for glimepiride, 0·98 (0·80—1·19) for glipizide, 1·13 (0·90—1·42) for tolbutamide, and 1·34 (0·98—1·86) for chlorpropamide.
Similar associations were noted for cardiovascular-related mortality: the relative risk compared with glibenclamide was 0·60 (95% credible interval 0·45—0·84) for gliclazide, 0·79 (0·57—1·11) for glimepiride, 1·01 (0·72—1·43) for glipizide, 1·11 (0·79—1·55) for tolbutamide, and 1·45 (0·88—2·44) for chlorpropamide …
Opracowane na podstawie: Lancet / 23 pażdziernika 2014